SEARCH

SEARCH BY CITATION

References

  • 1
    Jamison KR. Suicide and bipolar disorders. Ann N Y Acad Sci 1986; 487: 301315.
  • 2
    Müller-Oerlinghausen B, Muser-Causemann B, Volk J. Suicides and parasuicides in a high-risk patient group on and off lithium longterm medication. J Affect Disord 1992; 25: 261269.
  • 3
    Tondo L, Hennen J, Baldessarini RJ. Reduced suicide risk with longterm lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr Scand 2001; 104: 163172.
  • 4
    Baldessarini RJ, Tondo L, Hennen J. Lithium treatment and suicide risk in major affective disorders. Update and new findings. J Clin Psychiatry 2003; 64 (Suppl. 5): 4452.
  • 5
    Müller-Oerlinghausen B, Berghofer A, Ahrens B. The antisuicidal and mortality-reducing effect of lithium prophylaxis: consequences for guidelines in clinical psychiatry. Can J Psychiatry 2003; 48: 433439.
  • 6
    Angst J, Angst F, Gerber-Werder R, Gamma A. Suicide in 406 mood-disorder patients with and without longterm medication: a 40–44-year follow-up. Arch Suicide Res 2005; 9: 279300.
  • 7
    Kessing LV, Sondergard L, Kvist K, Andersen PK. Suicide risk in patients treated with lithium. Arch Gen Psychiatry 2005; 62: 860866.
  • 8
    Müller-Oerlinghausen B, Felber W, Berghofer A, Lautervach E, Ahrens B. The impact of lithium longterm medication in suicidal behaviour and mortality of bipolar patients. Arch Suicide Res 2005; 9: 307319.
  • 9
    Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behaviour and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005; 162: 18051819.
  • 10
    Tondo L, Isacsson G, Baldessarini RJ. Suicide in bipolar disorder: risk and prevention. CNS Drugs 2003; 17: 491511.
  • 11
    DerSimonian R, Laird NM. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177188.
  • 12
    Sweeting MJ, Sutton AJ, Lambert PJ. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of rare events. Stat Med 2004; 23: 13511375.
  • 13
    Bradburn MJ, Deeks J, Altman D. Updated and New Commands for Meta-Analysis in STATA®, Cancer Research UK Medical Statistics Group. Oxford: Centre for Statistics in Medicine. http://www.medepi.net/meta/software/Bradburn_metan_updates.pdf .
  • 14
    Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 10881101.
  • 15
    Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629634.
  • 16
    Baastrup PC, Poulsen JC, Schou M, Thomsen K, Amdisen A. Prophylactic lithium: double blind discontinuation in manic-depressive and recurrent-depressive disorders. Lancet 1970; 2: 326330.
  • 17
    Coppen A, Noguera R, Bailey J et al. Prophylactic lithium in affective disorders: a controlled trial. Lancet 1971; 2: 275279.
  • 18
    Prien RF, Klett CJ, Caffey EM, Jr. Lithium prophylaxis in recurrent affective illness. Am J Psychiatry 1974; 131: 198203.
  • 19
    Bech P, Vendsborg PB, Rafaelsen OJ. Lithium maintenance treatment of manic-melancholic patients: its role in the daily routine. Acta Psychiatr Scand 1976; 53: 7081.
  • 20
    Kay DWK, Petterson U. Manic-depressive illness. Acta Psychiatr Scand 1977; 269 (Suppl.): 5560.
  • 21
    Poole AJ, James HD, Hughes WC. Treatment experiences in the lithium clinic at St Thomas Hospital. J R Soc Med 1978; 71: 890894.
  • 22
    Glen AI, Dodd M, Hulme EB, Kreitman N. Mortality on lithium. Neuropsychobiology 1979; 5: 167173.
  • 23
    Ahlfors UG, Baastrup PC, Dencker SJ et al. Flupenthixol decanoate in recurrent manic-depressive illness. A comparison with lithium. Acta Psychiatr Scand 1981; 64: 226237.
  • 24
    Venkoba-Rao A, Hariharasubramanian N, Parvathi-Devi S, Sugumar S, Srinivasan V. Lithium prophylaxis in affective disorder. Indian J Psychiatry 1982; 23: 2230.
  • 25
    Glen AI, Johnson AL, Shepherd M. Continuation therapy with lithium and amitriptyline in unipolar depressive illness: a randomized, double-blind, controlled trial. Psychol Med 1984; 14: 3750.
  • 26
    Hanus K, Zapletàlek M. Suicidal activity of patients with affective disorders during the preventive use of lithium. Cesk Psychiatr 1984; 80: 97100.
  • 27
    Norton B, Whalley LJ. Mortality of a lithium-treated population. Br J Psychiatry 1984; 145: 277282.
  • 28
    Lepkifker E, Horesh N, Floru S. Longterm lithium prophylaxis in recurrent unipolar depression. A controversial indication? Acta Psychiatr Belg 1985; 85: 434443.
  • 29
    Page C, Benaim S, Lappin F. Longterm retrospective follow-up study of patients treated with prophylactic lithium carbonate. Br J Psychiatry 1987; 150: 175179.
  • 30
    Wehr TA, Sack DA, Rosenthal NE, Cowdry RW. Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients. Am J Psychiatry 1988; 145: 179184.
  • 31
    Nilsson A, Axelsson R. Lithium discontinuers. Clinical characteristics and outcome. Acta Psychiatr Scand 1990; 82: 433438.
  • 32
    Coppen A, Standish-Barry H, Bailey J, Houston G, Silcocks P, Hermon C. Does lithium reduce the mortality of recurrent mood disorders? J Affect Disord 1991; 23: 17.
  • 33
    O'Connell RA, Mayo JA, Flatow L, Cuthbertson B, O'Brien BE. Outcome of bipolar disorder on longterm treatment with lithium. Br J Psychiatry 1991; 159: 123129.
  • 34
    Vestergaard P, Aagaard J. Five-year mortality in lithium-treated manic-depressive patients. J Affect Disord 1991; 21: 3338.
  • 35
    Modestin J, Schwarzenbach F. Effect of psychopharmacotherapy on suicide risk in discharged psychiatric inpatients. Acta Psychiatr Scand 1992; 85: 173175.
  • 36
    Rihmer Z, Szanto K, Barsi J. Suicide prevention: fact or fiction? Br J Psychiatry 1993; 162: 130131.
  • 37
    Felber W, Kyber A. Suizide und Parasuizide während und ausserhalb einer Lithium prophylaxe (Suicide and parasuicide during and after lithium prophylaxis). In: Müller-OerlinghausenB, BerghöferA eds. Ziele und Ergebnisse der Medikamentosen Prophylaxe Affektiver Psychosen. Stuttgart: G. Thieme-Verlag, 1994: 5359.
  • 38
    Lenz G, Ahrens B, Denk E et al. Mortalität nach Ausschneiden aus der Lithiumambulanz (Increased mortality after drop-out from lithium clinic). In: Müller-OerlinghausenB, BerghöferA eds. Ziele und Ergebnisse der Medicamentösen Prophylaxe Affecktiver Psychosen. Stuttgart. G. Thieme-Verlag, 1994: 4952.
  • 39
    Müller-Oerlinghausen B. Die ‘IGSLi’ Studie zur Mortalität lithium behandelter Patienten mit affektiven Psychosen (The ‘IGSLI’ study of mortality in lithium-treated patients with affective psychoses). In: Müller-OerlinghausenB, BerghöferA eds. Ziele und Ergebnisse der Medikamentosen Prophylaxe Affektiver Psychosen. Stuttgart: G. Thieme-Verlag, 1994: 3539.
  • 40
    Sharma R, Markar HR. Mortality in affective disorder. J Affect Disord 1994; 31: 9196.
  • 41
    Ahrens B, Müller-Oerlinghausen B, Schou M et al. Excess cardiovascular and suicide mortality of affective disorders may be reduced by lithium prophylaxis. J Affect Disord 1995; 33: 6775.
  • 42
    Koukopoulos A, Reginaldi D, Minnai G et al. The longterm prophylaxis of affective disorders. In: GessaG, FrattaW, PaniL eds. Depression and Mania: from Neurobiology to Treatment. New York: Raven Press, 1995: 127147.
  • 43
    Nilsson A. Mortality in recurrent mood disorders during periods on and off lithium: a complete population study in 362 patients. Pharmacopsychiatry 1995; 28: 813.
  • 44
    Greil W, Ludwig-Mayerhofer W, Erazo N et al. Comparative efficacy of lithium and amitriptyline in the maintenance treatment of recurrent unipolar depression: a randomized study. J Affect Disord 1996; 40: 179190.
  • 45
    Greil W, Ludwig-Mayerhofer W, Erazo N et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders: a randomized study. J Affect Disord 1997; 43: 151161.
  • 46
    Greil W, Ludwig-Mayerhofer W, Erazo N et al. Lithium versus carbamazepine in the maintenance treatment of schizoaffective disorder: a randomized study. Eur Arch Psychiatry Clin Neurosci 1997; 247: 4250.
  • 47
    Bocchetta A, Ardau R, Burrai C, Chillotti C, Quesada G, Del Zompo M. Suicidal behaviour on and off lithium prophylaxis in a group of patients with prior suicide attempts. J Clin Psychopharmacol 1998; 18: 384389.
  • 48
    Coppen A, Farmer R. Suicide mortality in patients on lithium maintenance therapy. J Affect Disord 1998; 50: 261267.
  • 49
    Tondo L, Baldessarini RJ, Hennen J, Floris G, Silvetti F, Tohen M. Lithium treatment and risk of suicidal behaviour in bipolar disorder patients. J Clin Psychiatry 1998; 59: 405414.
  • 50
    Bauer M, Bschor T, Kunz D, Berghofer A, Strohle A, Müller-Oerlinghausen B. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry 2000; 157: 14291435.
  • 51
    Brodersen A, Licht RW, Vestergaard P, Olesen AV, Morensen PB. Sixteen-year mortality in patients with affective disorder commenced on lithium. Br J Psychiatry 2000; 176: 419433.
  • 52
    Kallner G, Lindelius R, Petterson U, Stockman O, Tham A. Mortality in 497 patients with affective disorders attending a lithium clinic or after having left it. Pharmacopsychiatry 2000; 33: 813.
  • 53
    Coryell W, Arndt S, Turvey C et al. Lithium and suicidal behaviour in major affective disorder: a case-control study. Acta Psychiatr Scand 2001; 104: 193197.
  • 54
    Rucci P, Frank E, Kostelnik B et al. Suicide attempts in patients with bipolar I disorder during acute and maintenance phases of intensive treatment with pharmacotherapy and adjunctive psychotherapy. Am J Psychiatry 2002; 159: 11601164.
  • 55
    Bowden CL, Calabrese JR, Sachs G et al. Placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Lamictal 606 Study Group. Arch Gen Psychiatry 2003; 60: 392400.
  • 56
    Calabrese JR, Bowden CL, Sachs G et al. Placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Lamictal 605 Study Group. J Clin Psychiatry 2003; 64: 10131024.
  • 57
    Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003; 290: 14671473.
  • 58
    Yerevanian BI, Koek RJ, Mintz J. Lithium, anticonvulsants and suicidal behaviour in bipolar disorder. J Affect Disord 2003; 73: 223228.
  • 59
    Angst J, Gamma A. Failures in suicide prevention. In: KoukopoulosA, GirardiP, eds. Therapeutic Failures in Bipolar Patients: New Strategies. Rome: G.Fioriti Editore, 2005, pp 45–51.
  • 60
    Gonzalez-Pinto A, Mosquera F, Alonso M et al. Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. Bipolar Disord 2006; 8: 618624.
  • 61
    Baldessarini RJ, Tondo L, Viguera AC. Effects of discontinuing lithium maintenance treatment. Bipolar Disord 1999; 1: 1724.
  • 62
    World Health Organization (WHO). International suicide rates [WWW document]. URL http://www.who.int/mental_health/Topic_Suicide/suicide_rates.html [accessed on 31 January 2005].
  • 63
    Miniño AM, Arias E, Kochanek KD, Murphy SL, Smith BL. Deaths: Final data for 2000. Nat Vital Stat Rep 2002; 50: 99 (Table 33).
  • 64
    Kessler RC, Berglund P, Borges C, Nock M, Wang PS. Trends in suicide ideation, plans, gestures and attempts in the United States, 1990–1992 to 2001–2003. JAMA 2005; 293: 24872495.
  • 65
    Thies-Flechtner K, Müller-Oerlinghausen B, Seibert W, Walther A, Greil W. Effect of prophylactic treatment on suicide risk in patients with major affective disorders: data from a randomized prospective trial. Pharmacopsychiatry 1996; 29: 103107.
  • 66
    Tondo L, Baldessarini RH, Floris G. Longterm effectiveness of lithium maintenance treatment in types I and II bipolar disorders. Br J Psychiatry 2001; 178 (Suppl. 40): 184190.
  • 67
    Baldessarini RJ, Tondo L, Hennen J, Viguera AC. Is lithium still worth using? Update of selected recent research. Harv Rev Psychiatry 2002; 10: 5975.
  • 68
    Bauer MS, Mitchner L. What is a ‘mood stabilizer'? An evidence-based response. Am J Psychiatry 2004; 161: 318.
  • 69
    Baldessarini RJ, Tarazi FI. Pharmacotherapy of psychosis and mania. In: BruntonLL, LazoJS, ParkerKL eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th edn. New York: McGraw-Hill Press, 2005: 461500.
  • 70
    Judd LL, Akiskal HS, Schettler PJ et al. Longterm natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59: 530537.
  • 71
    Post RM, Denicoff KD, Leverich GS et al. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry 2003; 64: 680690.
  • 72
    Joffe RT, MacQueen GM, Marriott M, Young TL. A prospective, longitudinal study of percentage of time spent ill in patients with bipolar I or bipolar II disorders. Bipolar Disord 2004; 6: 6266.
  • 73
    Baldessarini RJ, Salvatore P, Tohen M et al. Morbidity from onset in first-episode bipolar I disorder patients: The International-300 Study. Neuropsychopharmacology 2004; 29 (Suppl. 1): 88.
  • 74
    Ahrens B, Müller-Oerlinghausen B. Does lithium exert an independent antisuicidal effect? Pharmacopsychiatry 2001; 34: 132136.
  • 75
    Baldessarini RJ, Pompili M, Tondo L et al. Antidepressants and suicidal behaviour: are we hurting or helping? Clin Neuropsychiatry 2005; 2: 7375.
  • 76
    Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials. An analysis of the FDA database. Arch Gen Psychiatry 2000; 57: 311317.
  • 77
    Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviour. JAMA 2004; 292: 338343.
  • 78
    Baldessarini RJ, Pompili M, Tondo L. Suicidal risk in antidepressant trials. Commentary. Arch Gen Psychiatry 2006; 63: 246248.
  • 79
    Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants and placebo: analysis of FDA reports. Am J Psychiatry 2003; 160: 790792.
  • 80
    Gunnell D, Sapeiria J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo-controlled, randomized controlled trials, submitted to the MHRA's safety review. BMJ 2005; 330: 385389.
  • 81
    Martinez C, Rietbrock S, Wise L et al. Antidepressant treatment and the risk of fatal and nonfatal self-harm in first-episode depression: nested case-control study. BMJ 2005; 330: 389395.
  • 82
    Baldessarini RJ. Drug therapy of depression and anxiety disorders. In: BruntonLL, LazoJS, ParkerKL eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th edn. New York: McGraw-Hill Press, 2005: 429459.
  • 83
    Waddington D, McKensie IP. Overdose rates in lithium-treated versus antidepressant-treated outpatients. Acta Psychiatr Scand 1994; 90: 5052.
  • 84
    Watson WA, Litovitz TL, Klein-Schwartz W et al. 2003 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System (TESS). Am J Emerg Med 2004; 22: 386392.
  • 85
    Ahrens B, Muller-Oerlinghausen B, Grof P. Length of lithium treatment needed to eliminate the high mortality of affective disorders. Br J Psychiatry 1993; 162 (Suppl.): 2729.
  • 86
    Meltzer HY, Alphs L, Green AI et al. Clozapine treatment for suicidality in schizophrenia. International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60: 8291.
  • 87
    Hennen J, Baldessarini RJ. Reduced suicidal risk during treatment with clozapine: a meta-analysis. Schizophr Res 2005; 73: 139145.
  • 88
    Modestin J, Dal Plan D, Agarwalla P. Clozapine diminishes suicidal behaviour: retrospective evaluation of clinical records. J Clin Psychiatry 2005; 66: 534538.